期刊文献+

不同免疫抑制剂经核因子-κB信号途径调节肠上皮细胞防御素的表达

原文传递
导出
摘要 目的探讨4种不同免疫抑制剂(他克莫司、环孢素A、雷帕霉素、雷公藤多甙)对Caco-2和HT-29细胞人β防御素1和2(hBD-1/2)的表达影响及机制。方法通过实时定量聚合酶链反应(Real-timePCR)和Western blot检测终质量浓度为10μmol/L的4种不同免疫抑制剂对白细胞介素-1p(IL-1p,20μg/L)诱导的人肠上皮细胞hBD-1/2表达的影响,应用凝胶电泳迁移率实验法(EMSA)和酶联免疫吸附试验(ELISA)检测Caeo-2细胞核因子-κB(NF—κB)的表达。结果肠上皮细胞组成性表达hBD-1;他克莫司、环孢素A和雷帕霉素组在Caco-2细胞中hBD-2mRNA促进率分别为(20.58±1.02)%、(139.49±6.97)%和(425.97±21.29)%,雷公藤多甙组hBD-2mRNA抑制率为(48.59±2.42)%(P〈0.05)。HT-29细胞中上述指标分别为(62.52±3.25)%、(20.56±1.10)%、(46.79±2.28)%和(82.73±7.88)%(P〈0.05)。Caco-2细胞中hBD-2蛋白的表达与mRNA的表达趋势一致。EMSA和ELISA检测活化的NF-κB显示他克莫司、环孢素A和雷帕霉素组促进NF—κB的活化,雷公藤多甙组抑制NF—κB的活化。并与Ser276磷酸化有关。结论他克莫司、环孢素A和雷帕霉素促进人肠系细胞在IL-1β诱导下表达hBD-2,雷公藤多甙抑制hBD-2的表达。其机制与NF—κB信号途径有关。 Objective To investigate the effect of tacrolimus (FK506),cyclosporin A (CsA),rapamycin (Rapa) and Glucosida Tripterygii TOTA (GTT) on human β-defensin (hBD-1 and hBD-2) expression in intestinal epithelial cells (Caco-2 and HT-29 cells).Methods Quantitative real-time quantitative polymerase chain reaction (Real-time PCR) and Western blotting were used to detect the effects of the final concentration of 10 μmol/L of FK506,CsA,Rapa and GTT on hBD-1 and hBD-2 expression in human intestinal epithelial cells stimulated by interleukin (IL)-1 β (20 μg/L).Nuclear factor-κB (NF-κB)binding activity in the Caco-2 cells was examined by using electrophoretic mobility shift assay (EMSA) and an enzyme linked immunosorbent assay (ELISA)-based assay with immobilized oligonucleotide.Results As compared with the IL-1β alone,the addition of FK506,CsA or Rapa in the culture medium in Caco-2 cells significantly increased the mRNA level of hBD-2 by (20.58 ± 1.02)%,(139.49 ± 6.97)% and (425.97 ± 21.29)% respectively (P <0.05).Meanwhile,the mRNA level of hBD-2 was decreased by (48.59 ± 2.42)% in Caco-2 cells cultured with GTT (P< 0.05).In HT-29 cells,the value was (62.52±3.25)%,(20.56±1.10)%,(46.79 ±2.28)% and (82.73 ±7.88)% respectively (P<0.05).Western blotting analysis revealed that the same results.However,GTT attenuated the expression of hBD-2.As compared with the control group,either FK506,CsA and rapamycin promnoted the activation of NF-κB,but GTr decreased the activation of NF-κB (P < 0.05),which was related to the phosphorylation of Ser276.Conclusion The results presented in this paper show that FK506,CsA and Rapa activate NF-κB in intestinal epithelial cells,resulting in efficient induction of hBD-2 production in vitro.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2013年第5期961-963,共3页 Chinese Journal of Experimental Surgery
  • 相关文献

参考文献8

  • 1Lippross S,Klueter T,Steubesand N, et al. Multiple trauma inducesserum production of host defence peptides. Injury ,2012,43 : 137-142.
  • 2李广阔,李旭,田伏洲,曹永宽,陈涛.人源性空回肠粘膜防御素-5基因的克隆[J].中华实验外科杂志,2003,20(10):884-885. 被引量:3
  • 3Habets MG, Brockhurst MA. Therapeutic antimicrobial peptides maycompromise natural immunity. Biol Lett,2012 ,8 :416-418.
  • 4Dossel J,Meyer-Hoffert U,Schroder JM,et al. Pseudomonas aerugino-sa-derived rhamnolipids subvert the host innate immune responsethrough manipulation of the human beta-defensin-2 expression. CellMicrobiol ,2012 ,14 : 1364-1375.
  • 5Navid F,Boniotto M, Walker C,et al. Induction of regulatory T cells bya murine beta-defensin. J Immunol ,2012 ,188 :735-743.
  • 6Yang D, Chertov 0, Bykovskaia SN, et al. Beta-defensins:linking in-nate and adaptive immunity through dendritic and T cell CCR6. Sci-ence, 1999 ,286 :525-528.
  • 7Tsutsumi-lshii Y, Nagaoka 1. Modulation of human beta-defensin-2transcription in pulmonary epithelial cells by lipopolysaccharide-stimu-lated mononuclear phagocytes via proinilammatory cytokine produc-tion. J Immunol,2003 ,170:4226-4236.
  • 8李琦,于颖彦,朱正纲,刘炳亚,王理伟,林言箴.核因子-κB/p65反义寡核苷酸对胃癌细胞增殖和凋亡的影响及其机制[J].中华实验外科杂志,2008,25(8):1009-1011. 被引量:5

二级参考文献11

  • 1李琦,于颖彦,朱正纲,刘炳亚,纪玉宝,张奕,程琳玲,林言箴.核转录因子-κB组成性激活对胃癌细胞增殖的影响及其机制[J].中华实验外科杂志,2004,21(8):957-960. 被引量:12
  • 2黄涛,冯延平,常青,高军,杜志勇,秦仁义,裘法祖.β1整合素反义寡核苷酸对人胰腺癌BXPC-3细胞体外侵袭力的影响[J].中华实验外科杂志,2006,23(7):834-836. 被引量:8
  • 3Reuning U, Wilhelm O, Nishiguchi T, et al. Inhibition of NF-kappa B- Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res, 1995,23:3887 -3893.
  • 4Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene,2003 ,22 :9087-9096.
  • 5Stephens AC, Rivers RP. Antisense oligonucleotide therapy in cancer. Curr Opin Mol Ther,2003,5 : 118-122.
  • 6Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res ,2000,6:3739-3747.
  • 7Yuen AR, Branimir LS. Clinical studies of antisense therapy in cancer. Front Biosci ,2000,5:588.
  • 8Rait AS, Pirollo KF, Rait V, et al. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther,2001,8 : 728-739.
  • 9So A, Rocchi P, Cleave M. Antisense oligonucleotide therapy in the management of bladder cancer. Curr Opin Urol,2005,15:320-327.
  • 10Li WC,Ye SL,Sun RX,et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res, 2006,12:7140-7148.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部